Skip to content
Open access

Survival benefits of complete ablation in patients with BCLC stage B hepatocellular carcinoma receiving transarterial chemoembolization and systemic therapy

Nov 2026 · Discover Oncology · 0 citations

TL;DR

In patients with BCLC stage B HCC receiving TACE combined with systemic therapy, complete ablation was associated with improved survival and a model to identify patients most likely to benefit from the treatment was developed.

Abstract

The role of ablation in BCLC stage B hepatocellular carcinoma (HCC) remains unclear, particularly in the setting of transarterial chemoembolization (TACE) combination with systemic therapy. Our study assessed the impact of ablation on survival and developed a model to identify patients most likely to benefit from the treatment. This retrospective single-center cohort study included 230 patients with BCLC stage B HCC. Patients were classified into TACE plus systemic therapy (TACE + ST, n  = 103), TACE plus incomplete ablation with systemic therapy (TACE-IA + ST, n  = 42), and TACE plus complete ablation with systemic therapy (TACE-CA + ST, n  = 85) groups. The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). In the ablation cohort, a prognostic scoring was established from independent related factors for OS and internally validated using bootstrap resampling. Median PFS was 7.8, 9.9, and 12.3 months in the TACE, TACE-IA, and TACE-CA groups. Median OS was 45.0 months in the TACE group and 36.0 months in the TACE-IA group, whereas median OS was not reached in the TACE-CA group. Significant differences were observed among the three groups for both PFS ( P  = 0.0038) and OS ( P  < 0.001). In multivariable analysis, compared with TACE alone, TACE-CA was independently associated with improved PFS ( P  = 0.007) and OS ( P  = 0.002), whereas TACE-IA was not. After IPTW, TACE-CA remained associated with better survival. In the ablation cohort, a score based on tumor size, AFP, and treatment status showed good discrimination. In patients with BCLC stage B HCC receiving TACE combined with systemic therapy, complete ablation was associated with improved survival.

Read PDF

Similar papers

Open access Oct 2026

Survival benefits and prognostic models of surgical resection versus continued medical treatment in CNLC stage IIb/IIIa hepatocellular carcinoma after meeting resectability criteria following conversion therapy

Objective The combination of targeted therapy, immunotherapy, and locoregional treatment has established conversion therapy as a viable strategy for China Liver Cancer Staging (CNLC) stage IIb/IIIa hepatocellular carcinoma (HCC). However, upon meeting the criteria for tumor resectability after successful conversion, it...

Jia-Wa Qiu, Zheng-Hui Ye, Li-Ya Zhao et al. · 0 citations
Open access Oct 2026

The Efficacy and Safety of Combined Locoregional and Systemic Therapy versus Systemic Therapy Alone in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: A Multicenter Real-World Retrospective Cohort Study

Background To compare the efficacy and safety of combined locoregional and systemic therapy vs systemic therapy alone in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombosis (PVTT). Methods This multicenter retrospective study included 337 patients with HCC and PVTT who received systemic therap...

J. Liu, Yuxuan Lin, Kong-Ying Lin et al. · 0 citations
Open access Oct 2026

A cohort study on efficacy and safety of treatment modalities for resectable hepatocellular carcinoma with extrahepatic metastasis

Hepatectomy might provide a survival benefit over interventional and systemic therapy in carefully selected patients with resectable HCC and extrahepatic metastasis, particularly those with lung-only metastasis, preserved liver function, and no PVTT.

Tai-Xin Yang, Zhan Lu, Jie Zhang et al. · 0 citations
Open access Oct 2026

Development and internal validation of a pretreatment magnetic resonance imaging-based radiomics prediction model for 1-year overall survival in treatment-naïve patients with hepatocellular carcinoma receiving transarterial chemoembolization combined with targeted therapy and immune checkpoint inhib

Background Reliable pretreatment tools to identify treatment-naïve patients with intermediate-to-advanced hepatocellular carcinoma (HCC) who may benefit from this combination are lacking. We developed and internally validated a clinical-radiomics model based on pretreatment T2-weighted fat-suppressed magnetic resonance...

Cheng-Yi Jiang, Shuai Zhang, Bei-Guang Zhang et al. · 0 citations
Open access Oct 2026

Efficacy and safety of sintilimab plus bevacizumab with or without transarterial chemoembolization for unresectable hepatocellular carcinoma: a propensity score-matched retrospective cohort study.

Background To compare the efficacy and safety of transarterial chemoembolization (TACE) plus sintilimab and bevacizumab (triple therapy) versus sintilimab and bevacizumab alone (dual therapy) in unresectable hepatocellular carcinoma (uHCC). Methods This single-center retrospective cohort study enrolled consecutive pa...

Zi-Zhuo Wang, Bai-Lu Wu, Chun-Shu Wu et al. · 0 citations
Open access Oct 2026

Retrospective observational study of transcatheter arterial chemoembolization (TACE) combined with PD-1 inhibitor and tyrosine kinase inhibitor (TKI) in advanced hepatocellular carcinoma

Transcatheter arterial chemoembolization (TACE) induces tumor necrosis and antigen release, but the resulting hypoxic microenvironment upregulates programmed death-ligand 1and vascular endothelial growth factor, providing a biological rationale for adding a programmed death-1 (PD-1) inhibitor and a TKI. The study aims...

Guo-Hui Xu, Jian-Long Zhang, Xiao-Jun Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.